MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	10/13/2006 3:17:28 PM
	Read Replies (1) of 1826

MGI Pharma "neutral" Friday, October 13, 2006 5:34:54 AM ET Robert W. Baird NEW YORK, October 13 (newratings.com) - Analysts at Robert W Baird reiterate their "neutral" rating on MGI Pharma (MOGN.NAS). The target price is set to $17. In a research note published this morning, the analysts mention that the company has received an approvable letter from the FDA for its Saforis drug to be used in the treatment and prevention of oral mucositis. The FDA has asked for additional Phase III data on Saforis, which is expected to significantly delay the drug's launch time. MGI Pharma is likely to divest the drug or form a partnership to develop Saforis in the near future, Robert W Baird adds.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next